@article{ref1,
title="Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio",
journal="Drug and alcohol dependence",
year="2014",
author="Falck, Russel S. and Li, Linna and Martins, Silvia S. and Daniulaityte, Raminta and Nahhas, Ramzi W. and Carlson, Robert G.",
volume="134",
number="",
pages="259-266",
abstract="BACKGROUND: Increases in non-medical use of pharmaceutical opioids in the U.S. have resulted in increases in opioid dependence and unintentional overdose deaths. We characterize heterogeneity in opioid use patterns among a community-based sample of 18-23 year-olds who use non-medical pharmaceutical opioids, yet are not opioid dependent. METHODS: Respondent-driven sampling recruited 390 participants. Latent class analysis stratified by racial/ethnic group identified subgroups of non-medical opioid users based on: six-month frequency of use; number of opioid disorder criteria; oral vs. non-oral administration; number of types of opioids used; use of CNS depressants while under using opioids; and reason for opioid use. Multinomial logistic regression estimated the significance of covariates in predicting class membership. RESULTS: Within whites and non-white groups, three classes emerged that were, generally, hierarchically ordered with respect to negative characteristics associated with non-medical opioid use. Within each group, the class with the least negative characteristics also had the highest proportion of individuals who use opioids only to self-medicate a health problem. Within each group's three classes, a larger proportion who had ≥2 opioid abuse and dependence disorder criteria always coincided with a larger proportion who use opioids≥3 days per week, a larger proportion who used CNS depressants while under the influence of opioids, and a smaller proportion who used opioids only to self-medicate. CONCLUSION: Differences in patterns of opioid use within each racial/ethnic group of young people who are not opioid dependent suggest the need for tailored interventions designed to reduce the risk of transition to opioid dependence.<p /><p>Language: en</p>",
language="en",
issn="0376-8716",
doi="10.1016/j.drugalcdep.2013.10.004",
url="http://dx.doi.org/10.1016/j.drugalcdep.2013.10.004"
}